Contineum Therapeutics, Inc.
CTNMNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for CTNM. That does not mean none is planned.
Get an email about CTNM's next catalysts
Track Contineum Therapeutics (CTNM) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 2 past
No catalysts found.
Market Overview
Stock performance and key metrics
PIPE-791 Dose A
Idiopathic Pulmonary Fibrosis
PIPE-505
Sensorineural Hearing Loss
PIPE-307 Dose A
Relapsing Remitting Multiple Sclerosis
PIPE-791 Dose B
Idiopathic Pulmonary Fibrosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PIPE-791 Dose A | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
PIPE-505 | Phase 2 | Sensorineural Hearing Loss | - | - |
PIPE-307 Dose A | Phase 2 | Relapsing Remitting Multiple Sclerosis | - | - |
PIPE-791 Dose B | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Frequently asked questions
What is in Contineum Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Contineum Therapeutics, Inc.'s (CTNM) pipeline across Phase 2. Its lead program is PIPE-307 Dose A (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Contineum Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Contineum Therapeutics, Inc. (CTNM) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CTNM biotech catalysts?→
Add CTNM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Contineum Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.